VisEn Medical

VisEn Medical was a pioneer in fluorescence molecular imaging, specializing in the development of Fluorescence Molecular Tomography (FMT) systems and a broad portfolio of molecular imaging agents. The company's technology enabled researchers to non-invasively visualize and quantify biological processes and therapeutic efficacy in vivo at the molecular level. Their product line included 'smart' activatable probes such as ProSense and MMPSense, which target specific enzyme activities associated with cancer and inflammation. VisEn's solutions were integral to preclinical drug discovery, providing high-sensitivity data for monitoring disease progression. Founded in 2000 based on technology from Massachusetts General Hospital, the company established itself as a key player in the translational research market. In 2010, VisEn Medical was acquired by PerkinElmer for approximately $52.5 million to enhance its portfolio of molecular imaging and detection solutions.